Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise ...

Tejas Savant, an analyst from Morgan Stanley, maintained the Hold rating on Maravai Lifesciences Holdings (MRVI – Research Report). The associated price target was lowered to $7.00. Tejas Savant has ...

Maravai (MRVI) stock plunged 39% Friday, the day after the company issued a Q3 earnings report and revenue forecast that fell ...

Morgan Stanley lowered the firm’s price target on Maravai Lifesciences (MRVI) to $7 from $10 and keeps an Equal Weight rating on the ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) shares gapped down before the market opened on Friday after Royal Bank of Canada lowered their price target on the stock from $17.00 ...

Stay informed and make strategic decisions with our Ratings Table. Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies ...

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support ...

Fintel reports that on November 8, 2024, William Blair downgraded their outlook for Maravai LifeSciences Holdings ...

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Get to Know Maravai LifeSciences Better Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...